<DOC>
	<DOCNO>NCT00790413</DOCNO>
	<brief_summary>Children primary resistant relapse neuroblastoma achieve remission conventional chemotherapy extremely dismal prognosis . A novel treatment strategy combine tumor target radioisotope treatment metaiodobenzylguanidine ( MIBG ) immunotherapeutic effect haploidentical stem cell transplantation ( haploSCT ) follow low-dose donor lymphocyte infusion pilot . The use isotope aim decrease pre-transplant tumour burden . Reduced intensity condition contain Fludarabine , Thiotepa Melfalan enable sustain engraftment well serve additional anti-tumor treatment . A prompt natural killer ( NK ) -cell mediate tumour control may achieve haploidentical stem cell transplantation . The investigator hypothesize tumour cell potentially evade NK-cell mediated immunity may target infused donor T-cells eliminate either MHC-dependent manner bystander effect . The possible graft versus tumor effect evaluate child therapy resistant neuroblastoma .</brief_summary>
	<brief_title>Haploidentical Stem Cell Transplantation Neuroblastoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Refractory neuroblastoma ( chemo/radiosensitive stable disease ) Relapse incl . autologous HSCT 3 early Primary induction failure Cardiac output SF ≥25 % Creatinine clearance ≥40 cc/min/1.73 m2 Performance score ≥50 % ( Lansky Karnofsky ) Available haploidentical family donor , age ≥18 yr , HIVneg Rapidly progressive disease Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Radiotherapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
</DOC>